New hope for Tough-to-Treat gynecologic cancers: experimental drug combo enters human testing

NCT ID NCT04590326

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing a new experimental drug, REGN5668, alone and in several combinations with other cancer drugs, for people with advanced ovarian, fallopian tube, peritoneal, or uterine cancers that have progressed after standard treatments. The main goals are to find the safest dose and see if the treatments can shrink tumors. The study will enroll about 612 participants and is currently recruiting.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Francois Baclesse (CFB)
RECRUITING

Caen, Normandy, 14076, France
Centre Georges Francois Leclerc
RECRUITING

Dijon, Bourgogne-Franche-Comté, 21000, France
Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States
City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States
Ciudad Universitaria
RECRUITING

Madrid, 28040, Spain
Dana Farber Cancer Institute Brookline Avenue
RECRUITING

Boston, Massachusetts, 02215, United States
H. Lee Moffitt Cancer Center
COMPLETED

Tampa, Florida, 33612, United States
Hopital Lyon Sud
RECRUITING

Pierre-Bénite, Auvergne-Rhône, 69310, France
Hospital Clinico Universitario Santiago de Compostela
RECRUITING

Santiago de Compostela, A Coruna, 15706, Spain
Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Fundacion Jimenez
RECRUITING

Madrid, 28040, Spain
Institut Bergonie
RECRUITING

Bordeaux, Nouvelle-Aquitaine, 33076, France
Institut Catala dOncologia Girona
RECRUITING

Girona, 17007, Spain
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Perelman School of Medicine at the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States
Seattle Cancer Care Alliance at South Lake Union - G3630
RECRUITING

Seattle, Washington, 98109, United States
The City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
The Ohio State University Wexner Medical Center
RECRUITING

Columbus, Ohio, 43210, United States
Universitair Ziekenhuis Leuven
RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.

ENDOMETRIAL CANCER FALLOPIAN TUBE CANCER OVARIAN CANCER PRIMARY PERITONEAL CANCER